Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TIVICAY - Health Canada Drug Approval Details

Approvals/Health Canada/TIVICAY

Authorized

STANDARD

TIVICAY

viiv healthcare ulc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: d70c28e53b07424e
Company: viiv healthcare ulc
Type: Standard

Approval Details

Approval Id: d70c28e53b07424e
Drug Approval Canada Name: TIVICAY
Product Name: TIVICAY
Status: Cancelled Post Market
Status Date: 2024-12-31
Original Market Date: 2017-06-20
Din: 02461226
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 08:18.08.12
Atc Original: J05AJ03 DOLUTEGRAVIR
Atc Name: j 05 aj 03
Aig Number: 0154870003
Company Name: viiv healthcare ulc
Company Address: 1400, 75 Rue Queen, Montreal, Quebec, Canada, H3C 2N6

Active Ingredients

DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)

25 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

d70c28e53b07424e

Type

Standard

Back to Health Canada Approvals